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Abstract
Introduction: With the spread of the SARS-CoV2 pandemic,
telemedicine has become the safest way to guarantee care
continuity, especially for chronic disabling diseases re-
quiring frequent medical consultations and therapeutic ad-
justments, such as Parkinson’s disease (PD). The age-related
prevalence of PD, combined with increased vulnerability due
to age-related comorbidities, makes PD patients protection a
priority.
Methodology: We reviewed potentials and limitations of
teleneurology in PD and suggested a specific battery of tests,
including patient-reported outcomes, smartphone applica-
tions, and neurological examination through telemedicine.
Conclusions: These tools can provide full neurological con-
sultations, with the engagement of both patients and care-
givers, and can support clinicians in defining whether
patients need to access diagnostic and therapeutic proce-
dures. Telemedicine will also carry a value in the future,
within conventional health care, to support clinicians in de-
cision making, enabling more efficacious follow-up, reducing
burden for caregivers, and delivering neurological expertise to
local realities. These advantages are very important when
there is physical distance between patients and neurologists,
and when patients are not recommended to attend in-person
consultations.




he risk of infection from SARS-CoV-2 has raised
global public health concerns. The World Health
Organization (WHO) has declared COVID-19 pan-
demic on March 11, 2020.1 To date, several studies
showed that older adults2 and patients with chronic neuro-
logical disorders may be at increased risk of infection because
of either the disease itself or for disruptions in health care
provision.3
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder with an increasing prevalence with
aging, configuring a condition predisposing to a higher risk of
COVID-19.
In this emergency, outpatient appointments have been
cancelled or postponed, making telemedicine4 a useful tool to
ensure continuity of care5 and to reduce the risk of infection.
Therefore, digital health could provide people with PD (pwPD)
with customized consultations from movement disorders
specialists and general neurologists.6
Consultations for pwPD include both motor and nonmotor
symptoms (NMSs) evaluation. In outpatient settings, models
of care in PD are based on interview of patients and/or care-
givers, and targeted neurological examination. In the current
context, teleconsultations may help in overcoming outpatient
clinic restrictions.6
Indeed, over the past years, several studies have highlighted
the utility of e-health measures and wearable sensors to assess
patients remotely, providing objective parameters of motor














































and NMSs and connecting movement disorders or rehabili-
tation specialists to local health care providers.7
In pwPD, Beck et al. reported that telemedicine evaluation is
no less efficacious than in-person consultations, even with
more patient satisfaction.8
Methodology
In PD, the smart applications of standardized motor scales,
such as the Movement Disorder Society Unified Parkinson
Disease rating scale—part III–IV (MDS-UPDRS-III/IV), have
demonstrated to be almost as reliable as in typical outpatient
visits, although the evaluation of some clinical signs is pre-
cluded (i.e., rigidity) or can be checked only if safe and with
the help of caregivers.9 The app MDS-UPDRS (Doctot, Lim-
erick, Ireland) it is available in the European Union (EU) for
free at the Apple store and could be used with medical pro-
fessional guidance during teleconsultation.9 Similarly, in
smartphones using the Android operating system, another
app named CloudUPDRS app (Birkbeck College, University
of London, London, UK ) can be downloaded free of charge
from the Google store.10
In clinical practice, NMSs of PD may be sought in
clinical history with patient-reported outcomes (PROs),
including questionnaires assessing patients’ quality of life
and functional independence in daily living activities.
PROs are feasible online, positively perceived by patients
and their caregivers, and can help physicians in decision
making.11,12 Moreover, standardized acquisition of PROs
could enable early recognition of NMSs and other poten-
tially life-threatening symptoms, such as falls, autonomic
dysfunction, dysphagia, and neuropsychiatric/cognitive
symptoms.
The NMS Scale (NMSS) is the most applied tool to assess
NMSs. It consists of a 30-item rater-based scale to assess se-
verity and frequency of NMSs. It can be compiled in 10–
15 min and is available in multiple languages.13
The Conley Scale is a 6-item scale and could be performed
to promptly identify the risk of house falls, it can be completed
in 2 min and is available in several languages.14 Caregiver-
administered ADL/IADL (Activities of Daily Living/Instru-
mental Activities of Daily Living)15 could be informative
about rapid deterioration of patients’ autonomy. Ques-
tionnaire for Impulsive-Compulsive Disorders in Parkinson’s
Disease (QUIP)16 and Scales for Outcomes in Parkinson’s
Disease-Psychiatric Complications (SCOPA-PC)17 could be
used and may help recognizing the onset of neuropsychiatric
symptoms, which could reflect adverse effects of ongoing
pharmacological therapy or intercurrent medical complica-
tions that prompt rapid medical intervention.
Alongside with conventional outcome measures for motor
and nonmotor evaluation of PD, digital technology represents
a key support for remote monitoring. The use of an easy to
fulfill electronic diary could be recommended. The Parkinson’s
Diary (FieC &YL MIT Lab, Cambridge, Massachusetts) presents a
free application available on iOS and Android platforms, may be
very useful to record daily activities, feelings, and general health
status and is available in the EU.9,18 Other smartphone applica-
tions, with strong correlation with MDS-UPDRS-III total score,
could be considered to monitor pwPD and to evaluate some
clinical signs otherwise not assessable remotely: Lift Pulse,
available for free on iOS and Android (Lynx Design, National
Institutes of Health [NIH], Bethesda, Maryland), may be used to
record resting tremor. PD ME (Belles Farm LLC, University of
California Los Angeles, San Francisco Art Institute, California),
available free of charge at the Apple store can be used to test
memory, balance, reaction time, and time perception.9
Table 1. Suggested Battery for Assessing Parkinson’s





Available in multiple languages
Largely feasible remotely
Available for self-assessment
Available on iOS/Android system
Free download
To own a smartphone
Caregiver’s help




Conley Scale Available in multiple languages
Available for self-assessment
Small number of items






Available in multiple languages
Largely feasible remotely
Available for self-assessment
Available on iOS system
Free download



















Suggested tools for assessing PD disability on telemedicine and suggested
algorithm of administration.
MDS-UPDRS, Movement Disorder Society Unified Parkinson Disease rating
scale; NMSS, nonmotor symptoms scale; PD, Parkinson’s disease.
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Therefore, we suggest that pwPD should fulfill an electronic
diary monitoring physical and mental status and might use
the NMSS tool and the Conley scale to assess NMSs and the
risk of falls (Table 1).
Finally, when performing the teleconsultation, (1) move-
ment disorders specialists may acquire further anamnestic
details, such as symptoms of autonomic dysfunction, dys-
phagia, and rapid deterioration of cognitive status; (2) motor
symptoms can be evaluated with smartphone applications
MDS-UPDRS/CloudUPDRS, Lift Pulse, and PD ME; and (3)
caregiver-administered ADL/IADL could reveal reduction or
loss of patient’s autonomy in daily living.
Conclusions
We acknowledge that telemedicine has many limitations, both
device related (access to technology, webcam quality, high-speed
internet connection, etc.) and not device related (limited neuro-
logical examination, data protection regulation, etc.); however,
we foresee that the overall benefits of this approach will render
telemedicine progressively part of neurological clinical practice.19
The current global emergency from COVID-19 has boosted
the rapid reorganization of health care systems toward tele-
medicine, with the priority to defend safety while allowing the
patient to continue his or her diagnostic-therapeutic process.
Medical examination remains the cornerstone of practice,
but telemedicine decreases the number of patient atten-
dances as consultations take place through telephone, video
calls, exchanges of photographic documentation, mobile
phone messages, e-mail, or other applications for comput-
ers or mobile phones. Neurologists should be encouraged to
use telemedicine, as it could reveal as a useful tool to im-
prove quality of care in patients with chronic neurological
disorders. Even after the COVID-19 emergency, tele-
medicine will be essential to streamline outpatient visits,
while at the same time limiting costs.
In conclusion, telemedicine can offer a support to the
doctors’ activity by facilitating their work. In this sense, the
COVID-19 pandemic represents a positive input for the ac-
celeration and enhancement of these tools.
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18. Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE,
Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS,
Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C,
Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz
CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating
Scales Program Electronic Development Ad-Hoc Committee. The Parkinson’s
disease e-diary: Developing a clinical and research tool for the digital age. Mov
Disord 2019;34:676–681.
19. Bloem BR, Dorsey ER, Okun MS. The coronavirus disease 2019 crisis as catalyst
for telemedicine for chronic neurological disorders. JAMA Neurol 2020; [Epub
ahead of print]; doi:10.1001/jamaneurol.2020.1452.
Address correspondence to:
Luigi Lavorgna, MD
Department of Advanced Medical and Surgical Sciences





Received: May 20, 2020
Revised: June 22, 2020
Accepted: June 23, 2020
Online Publication Date: July 13, 2020
MIELE ET AL.
4 TELEMEDICINE and e-HEALTH MONTH 2020 ª MARY ANN LIE BERT, INC.
D
ow
nl
oa
de
d 
by
 1
51
.3
3.
24
1.
79
 f
ro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 1
0/
16
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
